Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma

With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sar...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrenk, Karin G., Weschenfelder, Wolfram, Spiegel, Christian, Agaimy, Abbas, Stöhr, Robert, Hartmann, Arndt, Gaßler, Nikolaus, Drescher, Robert, Freesmeyer, Martin, Malouhi, Amer, Bürckenmeyer, Florian, Aschenbach, René, Teichgräber, Ulf, Kögler, Christine, Vogt, Matthias, Hofmann, Gunther O., Hochhaus, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356868/
https://www.ncbi.nlm.nih.gov/pubmed/36469155
http://dx.doi.org/10.1007/s00432-022-04496-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356868/
https://www.ncbi.nlm.nih.gov/pubmed/36469155
http://dx.doi.org/10.1007/s00432-022-04496-y

Ejemplares similares